March 28 (Reuters) - Milestone Pharmaceuticals Inc MIST.O:
FDA ISSUES COMPLETE RESPONSE LETTER FOR ETRIPAMIL FOR PSVT
MILESTONE PHARMACEUTICALS INC - FDA RAISES NO CONCERNS ON ETRIPAMIL CLINICAL SAFETY OR EFFICACY
MILESTONE PHARMACEUTICALS INC - CRL FOCUSED ON CMC; NO CLINICAL ISSUES RELATING TO ETRIPAMIL RAISED
MILESTONE PHARMACEUTICALS INC - COMPANY TO SUBMIT ADDITIONAL INFO ON NITROSAMINE IMPURITIES
MILESTONE PHARMACEUTICALS INC - INSPECTION REQUIRED AT FACILITY PERFORMING ETRIPAMIL RELEASE TESTING
Source text: ID:nGNXZV9tl
Further company coverage: MIST.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.